SCOR SE (SWX:SCR)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 5.29B |
| Revenue (ttm) | 14.61B |
| Net Income (ttm) | 792.30M |
| Shares Out | n/a |
| EPS (ttm) | 4.36 |
| PE Ratio | 6.68 |
| Forward PE | 7.32 |
| Dividend | 1.69 (6.52%) |
| Ex-Dividend Date | May 2, 2025 |
| Volume | 250 |
| Average Volume | 68 |
| Open | 25.90 |
| Previous Close | 25.00 |
| Day's Range | 25.90 - 25.90 |
| 52-Week Range | 21.69 - 30.16 |
| Beta | 1.28 |
| RSI | 65.56 |
| Earnings Date | May 6, 2026 |
About SCOR SE
SCOR SE, together with its subsidiaries, provides life and non-life reinsurance products in Europe, the Middle East, Africa, the Americas, Latin America, and the Asia Pacific. It operates in two segments, SCOR P&C and SCOR L&H. The SCOR P&C segment offers reinsurance products in the areas of property, motors, casualty treaties, credit and surety, decennial insurance, aviation, marine and energy, engineering, cyber agricultural risks, and binders and facilities; It also provides business solutions including corporate risk insurance, as well as s... [Read more]
Financial Performance
In 2025, SCOR SE's revenue was 15.69 billion, a decrease of -4.68% compared to the previous year's 16.46 billion. Earnings were 851.00 million, an increase of 21175.00%.
Financial numbers in EURNews
SCOR SE announces the availability of its 2025 Universal Registration Document
The 2025 Universal Registration Document of SCOR SE (“SCOR” or the “Company”) prepared in ESEF format (European Single Electronic Format) was filed with the French Autorité des marchés financiers (“AM...
SCOR SE Earnings Call Transcript: Q4 2025
Record net income and ROE in 2025, with all segments contributing and cost savings ahead of plan. Dividend rises to EUR 1.9 per share, solvency ratio at 215%, and positive outlook for 2026 with continued disciplined growth and capital generation.
SCOR SE Transcript: Investor update
January 2026 renewals delivered 4.7% EGPI growth (excluding Alternative Solutions) and 80.5% growth in Alternative Solutions, with a -1.9% gross price change and a below 87% net combined ratio target. Cat exposures remain flat outside the US, with selective growth in US Cat and continued focus on underwriting discipline.
SCOR SE Earnings Call Transcript: Q3 2025
Q3 saw strong net income, robust P&C performance with a low combined ratio, and continued buffer-building in reserves. Life and health results are on track, investment returns remain solid, and the solvency ratio is stable. Focus is on underwriting discipline amid a more competitive market.
Information regarding the redemption by SCOR SE of outstanding €63.6 million undated subordinated notes
Press release 1 October 2025 - N° 17 Information regarding the redemption by SCOR SE of outstanding €63.6 million undated subordinated notes SCOR SE (the “Company”) announces the redemption of €63.6 m...
SCOR SE Earnings Call Transcript: Q2 2025
H1 2025 saw strong results with €225M net income, 22.6% ROE, and a 210% solvency ratio. P&C combined ratio was 82.5%, Life & Health performed well, and capital generation was robust. Guidance for 2025 P&C revenue growth is now flattish, with optimism for 2026.
SCOR - Second quarter 2025 results: EUR 226 million net income in Q2 2025, contributing to a EUR 425 million net income in H1 2025
Press release 31 July 2025 - N° 11 Second quarter 2025 results EUR 226 million net income in Q2 2025, contributing to a EUR 425 million net income in H1 2025 Group net income of EUR 2...
SCOR SE Earnings Call Transcript: Q1 2025
Q1 2025 saw strong net income, high ROE, and robust economic value growth, with all segments contributing positively. P&C outperformed on combined ratio despite cat losses, while life and health and investments delivered solid results. Guidance and outlook remain confident.
SCOR SE Combined Shareholders' Meeting held on Tuesday 29 April 2025 - Approval of all resolutions by SCOR SE shareholders
The Ordinary and Extraordinary Shareholders' Meeting of SCOR SE (the “Company”) was held today at the Company's registered office, 5, avenue Kléber, 75016 Paris, France, under the chairmanship of Fabr...
SCOR SE placed under examination for facts alleged against its former chairman
Press release 4 April 2025 - N° 06 SCOR SE placed under examination for facts alleged against its former chairman SCOR SE has been placed under examination as a legal entity in connection with a judi...
SCOR SE announces the availability of its 2024 Universal Registration Document
Press release 20 March 2025 - N° 04 SCOR SE announces the availability of its 2024 Universal Registration Document The 2024 Universal Registration Document of SCOR SE (“SCOR” or the “Company”) prepare...
SCOR SE Earnings Call Transcript: Q4 2024
Strong P&C performance and resilient balance sheet led to a positive full-year net income, with accelerated reserve buffer building and a 210% solvency ratio. Life and Health remains volatile but is improving, and a €1.8 dividend is proposed.
SCOR SE Transcript: Investor Update
January 2025 renewals delivered 9.6% EGPI growth, driven by specialty and Alternative Solutions, with stable expected profitability and disciplined risk management. Retrocession costs fell, exposures remain within risk appetite, and the Forward 2026 strategy is on track.
AM Best Removes From Under Review With Developing Implications and Affirms Credit Ratings of SCOR SE and Its Main Operating Subsidiaries
AMSTERDAM--(BUSINESS WIRE)-- #insurance--AM Best has removed from under review with developing implications and affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer C...
SCOR SE Transcript: Investor Day 2024
Confirmed 9% annual economic value growth and >12% ROE for 2025-2026, with accelerated cost savings, dynamic capital allocation, and a shift in Life & Health toward higher-margin, diversified business. P&C exceeded targets, buffer building is now opportunistic, and reserves are externally validated. Dividend policy and sustainability commitments remain unchanged.
SCOR SE Earnings Call Transcript: Q3 2024
Strong P&C and investment results were offset by a one-off Life and Health review impact, leading to a net loss and negative ROE, though underlying trends remain positive. Solvency ratio improved to 203% with new capital solutions, and reserve buffers in P&C are ahead of plan.
SCOR SE Earnings Call Transcript: Q2 2024
P&C and investment segments delivered strong growth and profitability, while life and health results were heavily impacted by a reserve assumption review, leading to a significant net loss and a downward revision of full-year targets. A three-step plan is underway to restore life and health profitability.
AM Best Places Credit Ratings of SCOR SE and Its Main Operating Subsidiaries Under Review With Developing Implications
AMSTERDAM--(BUSINESS WIRE)--AM Best has placed under review with developing implications the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) o...